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Radiotherapy treatment plans that are optimized to be highly conformal based on a static patient
geometry can be degraded by setup errors and/or intratreatment motion, particularly for IMRT
plans. To achieve improved plans in the face of geometrical uncertainties, direct simulation of
multiple instances of the patient anatomy to account for setup and/or motion uncertainties is used
within the inverse planning process. This multiple instance geometry approximation MIGA
method uses two or more instances of the patient anatomy and optimizes a single beam arrangement
for all instances concurrently. Each anatomical instance can represent expected extremes or a
weighted distribution of geometries. The current implementation supports mapping between in-
stances that include distortions, but this report is limited to the use of rigid body translations/
rotations. For inverse planning, the method uses beamlet dose calculations for each instance, with
the resulting doses combined using a weighted sum of the results for the multiple instances.
Beamlet intensities are then optimized using the inverse planning system based on the cost for the
composite dose distribution. MIGA can simulate various types of geometrical uncertainties, includ-
ing random setup error and intratreatment motion. A limited number of instances are necessary to
simulate Gaussian-distributed errors. IMRT plans optimized using MIGA show significantly less
degradation in the face of geometrical errors, and are robust to the expected simulated motions.
Results for a complex head/neck plan involving multiple target volumes and numerous normal
structures are significantly improved when the MIGA method of inverse planning is used. Inverse
planning using MIGA can lead to significant improvements over the use of simple PTV volume
expansions for inclusion of geometrical uncertainties into inverse planning, since it can account for
the correlated motions of the entire anatomical representation. The optimized plan results reflect the
differing patient geometry situations which can be important near the surface or heterogeneities. For
certain clinical situations, the MIGA optimization approach can correct for a significant part of the
degradation of the plan caused by the setup uncertainties. © 2006 American Association of Physi-
cists in Medicine. DOI: 10.1118/1.2191016
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The goal of radiotherapy treatment planning RTP for con-
formal therapy is to devise a plan that will accurately deliver
a tumorcidal dose of radiation to the clinical target volume
CTV while avoiding or reducing the dose to nearby
anatomy. While treatment planning typically is based on a
single volumetric imaging study obtained for planning, many
workers have reported the occurrence of localization errors
in clinical practice,1–8 while others have confirmed that in-
correctly localized patients suffer decreases in a positive
outcome.9–11 According to the International Commission on
Radiation Units Report 50 ICRU 50 recommendations,
these expected geometrical uncertainties should be ac-
counted for through the creation of a planning target volume
PTV that is defined by adding a margin around the CTV.12
The PTV then becomes the target volume used for planning
the high dose region. This recommendation ensures that the
CTV will have a high probability of being treated to the
desired dose over the course of treatment. Although normal
tissue geometrical uncertainties are frequently ignored, un-
1510 Med. Phys. 33 „5…, May 2006 0094-2405/2006/33„5…/1certainty in the normal tissue position is sometimes accom-
modated through the use of an expanded region around the
organ at risk OAR. Using the ICRU 62 recommendations,
the expanded region is called a planning organ at risk volume
PRV.13
Using these methods to account for geometrical uncer-
tainties has worked well for conformal planning, and careful
quantitation of these geometric uncertainties has become
critical for the successful implementation of 3D treatment
planning,14–19 provided the PTV and organs at risk are well
separated. However, when these normal and target tissues are
near each other or overlapping, then the absolute behavior of
these volumes is problematic, since it does not allow the
specification of the tradeoffs between sparing normal tissue
and giving the desired dose to the targets. These tradeoffs are
crucial, especially when inverse planning driven by optimi-
zation techniques is to be used. A second inherent problem
with multiple planning volumes is that there is no notion of
correlated motion of these structures. Often, particularly for
neighboring volumes, the motions of nearby structures are
well correlated i.e., the CTV and the OAR move together,
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take into account this correlation. These issues become in-
creasingly important for modern conformal therapy, where
IMRT is used to create highly conformal dose distributions,
particularly for situations where there are concavities in the
shape of the target volumes, or there are normal tissues
very close to the targets. The highly nonuniform dose dis-
tributions that are often obtained with IMRT plans lead to
another consideration for geometrical uncertainties: it is pos-
sible that an IMRT plan may be much more sensitive to
geometrical uncertainties than plans developed using flat ra-
diation fields, particularly where intra-treatment motion is
involved.20–25
There have been a number of studies into the effects of
geometric errors on dose distributions. Lujan et al. presented
the use of a convolution technique that involves taking the
three-dimensional dose calculation results for a given beam
arrangement and convolving it with a kernel that models the
positional probability distribution.26 That work included two
different uncertainty distributions; a Gaussian-shaped distri-
bution for random setup uncertainties as well as a kernel
modeling respiratory motion effects on tumors in the liver.
The dose-convolution method has also been described by
Craig et al.27,28 and others.29 The accuracy of such approxi-
mations has been examined by McCarter using direct simu-
lation of a limited number of fractions,30 rather than convolv-
ing the uncertainty distribution with the dose distribution,
Chetty et al. showed similar results with a Monte Carlo dose
calculation algorithm using a convolution of the uncertainty
distribution with the beam fluence.31 Organ motion has been
studied by Booth and Zavgorodni, who utilized Monte Carlo
simulations to examine the dosimetric consequences of organ
motion.32 All of the above approaches include the effects of
the geometric uncertainties a priori in the calculations them-
selves. Such an incorporation leads naturally to consider-
ations of planning methods aimed at direct coverage of the
CTV.33–35 However, implementation of this very concept
within the inverse planning process must be considered for
planning that incorporates use of IMRT.
Although there are many reports of the effect of geometri-
cal uncertainties on dose distributions delivered to the pa-
tient, there have been only a few reports attempting to fold
geometric uncertainties into the inverse planning process.
Löf, et al. presented a comprehensive theoretical analysis of
setup and motion uncertainty issues, and theoretically de-
scribed the incorporation of this analysis into their optimiza-
tion methodology.36 Birkner et al. has reported on a more
practical method of accounting for motion issues for optimi-
zation based on an “effective dose” generated by a sampling
of dose lookups for individual voxels or “subvolumes” based
on their spatial displacements for a collection of geometry
instances.37 This approach is similar to the MIGA technique,
except that in the Birkner work the dose is not recomputed
for each geometry instance. Li et al. have also demonstrated
a technique for incorporating organ motion into an optimiza-
tion system using a convolution technique to obtain a “mo-
38tion smoothed” dose distribution.
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must take into account the effects of geometrical uncertain-
ties, because any planned dose distribution is degraded by
various setup errors and intratreatment organ motion that oc-
curs over the course of many treatments. To design a treat-
ment plan that is robust against or tolerant of these uncer-
tainties, we make use of a multiple instance geometry
approximation MIGA that uses a few representative models
of the patient geometry to simulate motions that are likely to
occur during delivery of multiple treatments. In the present
work, random geometrical uncertainties are modeled using a
limited number of representative geometries, and only rigid
body transforms are used though future work will exploit
the capability of the model to handle distorted datasets and
anatomy. For IMRT plans, explicit beamlet dose calcula-
tions are done for each instance of the geometry and the
resulting calculations are then summed using the expected
population density weights, following, in general, the frame-
work proposed by Lof.36 In this paper we describe details of
the MIGA implementation, initial tests to demonstrate the
functionality, and then illustrate the method using the com-
plete analysis of a complex IMRT plan for the head/neck.
II. MATERIALS AND METHODS
Implementation of the multiple instance of geometry ap-
proximation MIGA methods described in this paper into
our existing treatment planning and optimization system has
required relatively few changes. The system consists of UM-
Plan, the in-house developed planning system that has been
used in our clinic for the past 20 years;39–43 a convolution/
superposition dose calculation based on work by Mackie44
module that had been modified to track the dose according to
a predefined fluence grid beamlets45 or to multiple
segments;46 and an inverse planning and optimization system
UMOpt47,48 used for beamlet and multisegment IMRT opti-
mization. The MIGA implementation described below in-
cludes 1 mechanisms for describing motion experiments,
2 support for multiple geometry instances, 3 methods
used for the definition of beam parameters, 4 the ability to
perform and track beamlet dose calculations for each geom-
etry instance, and 5 the optimization technique utilizing the
MIGA anatomies. Tests on phantom cases and a clinical
head/neck case are also described.
A. Motion experiments
For analysis of any single plan with respect to geometric
uncertainties, or for optimization of that plan in the face of
geometric uncertainties, we have defined the infrastructure to
allow the creation of “motion experiments.” Each motion
experiment describes one particular way of including geo-
metrical uncertainties into the planning, dose calculation,
and/or optimization process. For example, the user might
specify a multiple-instance MIGA experiment consisting of
seven different instances, in order to compare this “experi-
ment” to the result of a dose-convolution version of the plan,
or against the static version of the plan.
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stances to be used for MIGA, the motion experiment infor-
mation is described using a simple text file using keyword-
value pairs to specify 1 the experiment description, 2 the
geometry instance selection datasets as described below,
3 the relative weights population density weights, 4 the
motion experiment method. One can choose to use 1 the
MIGA approach, 2 a convolution of a position probability
distribution for random setup uncertainties, or 3 a breathing
motion kernel as described by Lujan49 to evaluate the effects
of respiratory motion.
B. Patient geometry instances
The UMPlan treatment planning system has from its ini-
tial design supported the use of multiple anatomical
datasets.39 This feature has been generally used to allow the
integration of data from multiple imaging sources,40,50 but is
quite suitable for the description of multiple patient anatomi-
cal descriptions geometry instances that are used in the
MIGA implementation. A 44 transformation matrix is used
to describe the transformations of each dataset relative to a
common reference system the treatment reference
system.39 One useful enhancement to the existing system
allows the definition of duplicate datasets that can then be
used to implement rigid body translations/rotations, which is
the way that the multiple MIGA datasets are currently used.
For each of these duplicate datasets, all anatomical informa-
tion is duplicated, including associated contours, surfaces,
and other information. Once the duplicated dataset is de-
fined, the desired transformations translation and rotation
operations can be defined using the dataset registration or
deregistration, in this case options in the planning system.
Within the MIGA infrastructure, it is also possible to
handle non-rigid body transformations between datasets. In
this case, the individual datasets truly represent different ge-
ometry instances that are derived from different imaging
studies e.g., CT scan sets taken on different days or taken at
different phases of the respiratory cycle. In these cases,
there may still be some rigid body transformations that will
place the multiple imaging studies into basic alignment,
however, a more complex mapping between different
datasets may be used. An example of this mapping might be
the use of thin plate splines with control points to map the
distortions involved in the lung due to respiration.51 Since
various techniques for this distortion mapping are currently
being investigated, the motion experiment infrastructure uses
a secondary file that describes the mapping between datasets
using a series of corresponding control points sufficient to
describe a warping transformation e.g., using thin plate
splines25 for interpolation. Further study of MIGA with dis-
torted instances will be performed once the distortion map-
ping research currently underway is completed.
When performing beamlet optimization, the patient ana-
tomical descriptions included in each dataset multislice
contours and derived surfaces are used to form a voxel-
based volumetric description of individual regions or com-
binations of regions. These regions are then sampled using
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a list of geometrical points to be used for dose calculation
and evaluation. For MIGA motion experiments, the same set
of points is applied to the different geometry instances
datasets using the geometrical mapping transforms.
An important issue for MIGA or any method handling
geometric uncertainties is the appropriate definition of the
target volumes. Normally, clinicians define the gross tumor
volumes GTVs and/or clinical target volumes CTVs
that describe the regions to be irradiated. Conventionally, one
would add a margin to this volume to form a planning target
volume PTV that then represents a volume that will ensure
adequate coverage of the CTV, despite the geometrical un-
certainties. As we are now attempting to account for this
motion more explicitly, the target volume that should be used
for planning with MIGA is not the conventional PTV vol-
ume, but something more like the CTV. How to accurately
define this CTV, and which errors and uncertainties are to be
contained within the CTV, are beyond the scope of this work.
Here, we will take the CTVs to be the volumes to which
we wish to deliver the treatment prescriptions, while in-
cluding geometrical uncertainties due to random setup errors
and/or intratreatment motion using the MIGA concept.
C. Plan definition and beam setup
Typically IMRT planning begins with a preselected set of
beams that are placed around the patient 1 uniformly in an
axial plane, or 2 with directions determined interactively
based on traditional “forward planning” experience. Each
beam’s apertures is typically formed so that the PTVs are
covered. Using a Beam’s Eye View BEV display is the best
way to ensure geometrically that there will be adequate tar-
get coverage and that normal tissues irradiation will be mini-
mized. In UMPlan, it is possible to display within the BEV
not only the nominal reference anatomy, but also the ana-
tomical information from the other shifted or warped
datasets. This allows the planner to enlarge jaw and MLC
boundaries to account for the expected as modeled by the
MIGA datasets motions of the clinical target volumes. For
IMRT optimization, a beamlet grid is defined resolution
typically 11 cm or 0.50.5 cm defined at the source to
axis distance. These grid elements are initially set to match
the rectangular jaw shape but those beamlets that fall outside
of the BEV target projection are normally defined to receive
an intensity of 0 and are excluded from the beamlet intensity
optimization.
D. Dose calculation methods
The calculation method used for normal non-MIGA
beamlet IMRT planning utilizes a convolution superposition
CVSP algorithm.44 The algorithm has been modified to
track the dose to each point per unit fluence through each
beamlet.45 In effect, the dose contribution of each beamlet a
rectangular cross section of the primary beam fluence or pen-
cil beam is calculated. Note that the convolution calculation
propagates dose through dose spread arrays that are corrected
for density changes between the primary interaction site and
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dose is computed to the set of points defined within each
region of interest, and so the dose per point per unit beamlet
intensity is computed for each beamlet.
For the multiple geometry instances used here, the dose
calculation procedure is exactly the same, except that the
calculations are repeated for each of the different geometry
instances. The geometrical shifts between the different
datasets affect both the density grid used for heterogeneity
corrections and the positions of the calculation points rela-
tive to the beam. For each dataset, the same beamlet descrip-
tion is used, and the calculations are again computed to the
same but shifted or warped set of points for each region.
The following equation is used to determine the effective




Wi Di, j,k , 1
where the effective dose Dj ,k represents the unit inten-
sity motion-weighted beamlet dose for point j and beamlet k.
This dose represents the weighted sum of the beamlet doses
Di , j ,k for each geometrical instances i. The weight Wi for
each instance represents the integral probability for a particu-
lar geometrical instance normalized so that i=1
n Wi=1.0.
E. Optimization
For normal non-MIGA optimization, individual beamlet
doses are retrieved, and the weights of each beamlet are op-
timized using cost function scoring that is based on the sum
of the dose to each point from all beamlets. The UMOpt
system uses a flexible cost function methodology that allows
a wide range of functions to be used to assign a cost for dose
to individual regions.47 The costs an individual region can
have multiple costs or “costlets” for each of the different
regions are combined to form a total cost for the plan. Simu-
lated annealing, quasi-Newton, or pre-emptive lexicographic
ordering search engines are used to drive the weight adjust-
ments based on the changes in the total cost or energy of
the system.
For MIGA optimization, the calculational results from
each of the datasets are retrieved, and the beamlet doses per
unit intensity for each point are summed using the probabil-
ity weights from the motion experiment file. Different prob-
ability weightings specified in different experiment control
files can be assessed without having to recalculate the point
doses. The resulting point doses, which are the motion-
averaged dose to each point per unit intensity, are then used
to determine the beamlet weights that result in the optimal
cost function result, just as is done in the static planning
case. Dose volume histograms DVHs are calculated using
the dose points contained in each structure, just as in the
non-MIGA case. The DVH analyzes the dose delivered to
each point over the patient treatment course as approximated
by the MIGA weighted multiple instances.
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For the initial testing of the MIGA concepts, a cylindrical
phantom 30 cm diameter was defined with a centered target
sphere of 6 cm diameter, both with unit density. A normal
cord-like object of 1 cm diameter and 10 cm length was
placed near the target. Multiple datasets were then defined to
delineate a series of shifts along various axes to document
the correct behavior of the various software features involved
in the MIGA method. For the tests described here, 13
datasets were defined with offsets in a direction parallel to
the centers of the target and cord structures with offsets of 0,
and ±2, 4, 6, 8, 10, and 15 mm. Three nonopposing beams
were then used for the initial testing, including testing of
various fields using beamlet grids of 22 mm, 55 mm,
and 1010 mm. The beamlets were defined to cover the full
range of the motion of the target. Figure 1 shows the geom-
etry, beam arrangement, and beamlet patterns for the 5
5 mm plan.
To demonstrate the results obtained with the MIGA-based
optimization, and to assess the sensitivity of the results to the
number of instances needed to approximate a Gaussian-
distributed uncertainty distribution of setup errors, three dif-
ferent population density distributions, each represented by a
Gaussian with a full width half max FWHM of 4, 8, and
12 mm in a direction perpendicular to the beam direction
were evaluated. For each Gaussian distribution, we opti-
mized initially identical plans, based on using 1, 3, or all 13
instances. For the three instance experiment, the nominal
dataset was included in the mix using a weight of 0.5 for the
unshifted dataset and 0.25 for the shifted datasets. The 13
datasets were weighted according to the Gaussian probabili-
ties for each of the displacements. Figure 2 illustrates the
weights used for the different number of instances used for
the 12 mm FWHM experiments.
Each plan was optimized using each of the geometry ex-
periments. The cost functions used for these tests had as
goals a target dose of 100 with a tolerance of ±2% with a
powered dose difference penalty the plan was penalized if
the dose dropped below 98% or above 102% and the penalty
was the dose difference below or above the tolerance win-
dow, to the power of six summed and averaged for all points
within the region. To reduce the dose outside of the target
region, the surrounding region was assigned a penalty using
a threshold function that penalized any doses above zero us-
ing the dose difference. The cordlike structure was penalized
with a threshold function starting at a relative dose level of
60% and the difference above was penalized to a power of 5.
All plans were then evaluated on the 13 instance dataset that
more accurately represents the full Gaussian distribution
i.e., the “truth” for this experiment.
G. Clinical example
To demonstrate the use of the MIGA technique in a real-
istic clinical situation, a MIGA optimization for a clinical
head/neck IMRT plan is compared to a static IMRT plan. The
planning protocol followed for this comparison is used for a
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the RTOG H0022 Head/Neck IMRT study.55 For this com-
parison, target volume doses of 66, 60, and 54 Gy were pre-
scribed for the high risk volumes, high risk nodes, and con-
tralateral nodal volumes, respectively, as shown in Fig. 3.Medical Physics, Vol. 33, No. 5, May 2006The cost functions used for the two optimization trials are
listed in Table I, and require a uniform ±5%  dose to each
of the targets, dose 45 Gy to the spinal cord, attempt to
reduce the mean dose to the parotids below 26 Gy, and mini-
mize all other normal tissue doses. For this simple example,
FIG. 1. Test phantom with three non-
opposed IMRT beams. Beamlets per
beam are constrained to the potential
motion displacement, which is
±15 mm in the direction between the
target yellow and the cord green.
FIG. 2. Dataset weights for 1- de-
fault, 3- 0, ±6 mm, and 13-
0, ±2, ±4, ±6, ±8, ±10, ±15 mm
instance distributions for the 12 mm
FWHM uncertainty distribution.
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for the static and MIGA IMRT plans Fig. 3.
The MIGA dataset was constructed by replicating the
original CT dataset six times and shifting the datasets in each
of the ±x, y, and z directions. The full MIGA anatomy thus
contained 7 datasets the original with weight 0.5, and the 6
shifted datasets, each with a weight of 0.0833, as shown
schematically in Fig. 4. The shifts used for each direction
were determined by the setup uncertainties measured for
similar head/neck patients in our clinic,56 and in this case
were ±0.42 cm ant-post, ±0.75 cm sup/inf, and ±0.45 cm
left/right. While the MIGA plan was optimized to give the
appropriate dose to the CTV’s drawn by the physician for
each of the targets, the static plan was optimized to deliver
the desired dose to a planning target volume PTV created
by anisotropic 3-D expansions of the individual CTVs using
margins of 0.42 cm ant/post, 0.75 cm sup/inf, and
0.45 cm lat, which is our normal approach to account for
TABLE I. Prioritized goals for head and neck parotid sparing protocol.
Cord Max45 Gy
Cord+5 mm Max50 Gy
Primary GTV, boost CTVs 66 Gy
Ipsilateral nodes 60 Gy
Contralateral and retropharyngeal nodes 54 Gy
Target homogeneity ±5%
Parotiods Mean dose26 Gy
All normal tissue MinimizeMedical Physics, Vol. 33, No. 5, May 2006this setup error distribution. Since the PTV created for some
CTVs extended outside the surface of the patient a common
problem for inverse planning in the head/neck, modified
PTVs were created by editing the PTVs back to the patient
surface “PTV-s”, or 5 mm inside the patient surface “PTV-
5”. For this simple clinical example, the “MIGA,” “PTV,”
“PTV-s,” and “PTV-5” plans were all evaluated on the seven-
instance MIGA dataset. Results of the dose volume histo-
grams obtained for these static and MIGA plans, using the
seven-instance MIGA dataset, are analyzed.
FIG. 3. Clinical example of a five axial
field head/neck IMRT plan: Targets
pink, red, yellow get doses of 66, 60,
ande 54 Gy. Cord green, Cord
+5 mm white, larynx white, pa-
rotids yellow, eyes red, and oral
cavity gray are also shown.
FIG. 4. The 7-instance MIGA dataset, with weights 0.5 center and 0.083
outside edges, and shifts from the nominal dataset of ±0.42 cm ant/
post, ±0.75 cm sup/inf, ±0.45 cm left/right.
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A. Test geometries
The results of the simple test geometry experiments Fig.
2 shows the geometry setup for the nominal dataset no
shift are illustrated in Fig. 5. The range of beamlets for the
lateral fields account for the maximum expected excursion of
±1.5 cm for the experiments analyzed. As one would expect,
optimizing with the multiple instance geometry approxima-
tion results in the beamlet weights being increased along the
direction of motion between the two instances to ensure
dose coverage of the target. Figure 5 demonstrates the dose
volume histogram DVH results for an anticipated random
uncertainty in the positioning along the direction between the
target and the cord-like object. The results are shown for the
static 1-instance versus 3-instance, and 13-instance
datasets, assuming a Gaussian distribution with a FWHM of
12 mm. For the static case, a PTV was used and was ex-
panded by ±6 mm in the direction of the anticipated motion.
This comparison shows how closely the static and 3-instance
MIGA plans agree with the 13-instance MIGA plan, which in
this case represents the best that could be achieved given the
particular random motion assumption. Figure 5 demonstrates
that the single instance example achieves adequate target
coverage through the use of the PTV definition. However,
the cord DVH for the PTV plan shows a higher dose than
resulted with any of the MIGA optimized plans. The
3-instance DVH matches closely with the 13-instance DVH,
indicating that a limited number of instances can be used to
approximate the assumed Gaussian motion.
B. Clinical head/neck example results
Dose volume histograms DVHs for the targets and nor-
mal tissues for this example case are shown in Figs. 6a,
6b, and 6c. Target volume comparisons are shown in Fig.
FIG. 5. Dose volume histogram for test phantom case with 3 nonopposing
beams optimized with 1- no motion, 3-, and 15-instance datasets evalu-
ated using the 15 Gaussian datasets for a motion compromised geometry
with FWHM of 8 mm.6a, which shows the PTV plan and MIGA plan doses to the
Medical Physics, Vol. 33, No. 5, May 2006CTVs CTV66, CTV60, CTV54. The CTV doses are com-
pared since the goal of both the MIGA optimization method
and the PTV expansion is to assure that the dose delivered to
the CTVs is the prescribed dose, even in the case of setup
uncertainty. The plots in Fig. 6a show that both the PTV
FIG. 6. a DVHs for the three targets CTV66, CTV60, and CTV 54. b
DVHs for normal tissues R and L parotid and spinal cord. c DVHs for
normal tissues cord+5 mm, and oral cavity. Results also shown for PTV-s
for surface limited PTV and PTV-5 for PTV restricted to be 5 mm inside
surface.and MIGA plans correctly cover all the CTVs with the de-
1517 McShan et al.: Optimization with MIGA 1517sired doses, as they should. Note, however, that the MIGA
DVHs do a better job of keeping the dose to the lower dose
CTVs down closer to their prescribed doses, rather than the
PTV plans, which must give the lower dose CTVs more dose
to cover the PTVs for the high dose targets since those
PTVs overlap the lower dose CTVs. Figures 6b and 6c
show the DVHs for the normal tissues, illustrating that the
MIGA method significantly decreases the dose delivered to
all normal tissues when compared to the PTV plans.
One of the regions that is significantly affected by setup
error is the buildup region and skin, especially where beams
tangentially irradiate the skin. One finds that there are often
large intensities in the beamlets that tangentially intersect the
patient surface. In contrast to many of the usual tricks used
to handle target regions very near the surface, including the
addition of virtual bolus, resetting the depth of buildup re-
gion calculation points to the depth of dmax and others,
MIGA plans can do accurate calculations to the buildup re-
gion points, since correct geometry is used for the dose cal-
culations for each dataset instance in the MIGA plans. MIGA
plans, since they take into account the potential setup differ-
ences, do not have the same high beamlet fluences at the
FIG. 7. a Two regions highlighting the dose to the skin were delineated—on
b DVHs for the PTV and MIGA plans to the two surface regions. c Later
of each point is defined by the dose using the displayed color table. d Lat
the lateral surface of neck, as well as the improved sparing of the parotid.patient surface. This is shown by looking at the DVHs for
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to the buildup region 1 for Surf-1, the region near the target
volumes; and 2 for Surf-2, a surface region away from the
target volumes. The DVHs for these two structures Fig.
7b show that while the dose near the surface from the PTV
plan might be as large as 100 Gy when evaluated over the
MIGA 7-instance dataset, the MIGA plan can keep these
doses lower, as desired to minimize patient skin reactions.
The overall improvement in dose distribution, especially on
the lateral aspect of the neck, can be seen by comparing Figs.
7c and 7d, which show the dose to each point calculated
within the patient, for the PTV and MIGA plans respectively.
The MIGA plan clearly shows lower doses along the lateral
aspect of the neck, and also clearly shows decreased dose to
the parotid.
One more interesting point about the MIGA plan solutions
is illustrated by Fig. 8. The MIGA solutions are not simply a
blurred out version of the PTV plan. Rather, the optimization
finds a different solution when the MIGA method is used.
This is illustrated by comparing the fluence distributions for
beam 1 of the PTV and MIGA plans, where the fluences are
ediately next to the target volumes, and another not directly next to targets.
w of dose distribution all calculated points due to the PTV plan. The color
iew of dose distribution due to MIGA plan. Note the decreased dose alonge imm
al vie
eral vquite different. In this anecdotal example, the type of inten-
1518 McShan et al.: Optimization with MIGA 1518sity patterns chosen by the optimization were clearly differ-
ent, an effect which could benefit from further study.
IV. DISCUSSION
In recent years, a great deal of effort has been spent de-
lineating the scope of various kinds of geometrical errors in
radiation therapy treatment planning and delivery. It is clear
that clinical 3-D conformal therapy treatment, with its dose
distributions tightly conformed to the target volumes, may
be highly sensitive to both systematic and random setup er-
rors, as well as to intratreatment motion. The use of IMRT
treatment delivery, with highly modulated intensity distribu-
tions within each radiation field, may be even more sensitive
to these geometric errors. Therefore, an understanding of the
various types of patient motion, and optimization of the plan
so that the degradation of the planned treatment due to such
motions is minimized, is critical for radiotherapy treatment
planning.
Fractionated radiation treatment involves patient localiza-
tion errors setup errors introduced by the imprecision of
day to day patient setup, physiological changes, and also by
intratreatment motion throughout the course of each fraction.
The only accommodation that the typical treatment planning
process makes for these “motions” is the use of simple mar-
gins around the target volume e.g., the PTV designed to
assure that the CTV is always included in the high dose
region, even as the various geometric motions occur. As
mentioned before, this simple margin-based approach runs
into difficulties whenever the expanded volumes either PTV
or PRV Planning Risk Volume overlap, since any overlap
of the volumes makes it impossible to fulfill the goal of the
expanded volumes without requiring some sort of tradeoff to
be made. This is particularly crucial when optimization tech-
niques are used, as in the case of inverse planning for IMRT.
In inverse planning, the inverse plan’s cost function deter-
mines how best to deliver the desired dose to the targets
while at the same time minimizing the dose to normal tis-
sues, rather than simply using the PTV margin to assure that
the target volume will be treated, regardless of the implica-
tions for surrounding normal tissues. In order to create a
treatment plan that is not degraded by the setup errors and
motion that occur during treatment, the plan must be created
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and motion distributions into the plan optimization process.
The MIGA method thus creates a model of the patient
geometry that can incorporate the geometrical setup error
and intratreatment motion expected for the patient. This de-
scription is formed by the use of multiple instances of the
patient geometry, weighted to best represent the expected
distribution of patient geometries that will be encountered
during the treatment course. The instances can be simple
duplicates of the original CT dataset, translated to represent
the random setup error for the patient, or they can be inde-
pendent CT datasets acquired at different times, or for differ-
ent phases of the respiratory cycle, for example. While in this
work we have considered only simple translations of dupli-
cate datasets, representing random setup errors, the MIGA
infrastructure can be used for much more complex represen-
tations of the situation. These more complex representations
will be studied in more detail in forthcoming publications.
In the simple phantom experiments, all of the different
multiple instance representations showed improved results
for the MIGA-based plans over the use of a simple static
plan. As expected, the use of a large number of instances
provides a more accurate simulation of the potential motions
than using a fewer number of instances. However, since the
calculation time and computer resources necessary for the
calculation depend on the number of instances, it is appro-
priate to try to find the minimal number of instances which
may be representative of the actual expected distribution of
geometries. Figure 5 demonstrated that the three-instance
dataset nominal plus two extremes did a reasonable job of
representing the full Gaussian uncertainty distribution, so we
have used this kind of MIGA dataset seven instances when
used in 3-D for our initial clinical examples. However, it is
clear that more work is necessary to determine the best rep-
resentations to be used for clinically relevant problems.
Another issue still to be addressed in future work involves
the size of the beamlets and how that interacts with the range
of motion involved in the Gaussian uncertainty distribution,
including specifically the distance between different in-
stances. For large beamlet grids and small uncertainties, it is
expected that it will be difficult for the optimization to re-
spond to the small geometric uncertainties, while small
FIG. 8. Example intensity distributions
for Beam 1: PTV plan, MIGA plan,
difference PTV plan—MIGA plan.beamlets and larger distances between the instances may lead
1519 McShan et al.: Optimization with MIGA 1519to quite different response of the optimization to the incor-
poration of the multiple instances into the optimization pro-
cess including possibly aliasing. A reasonable rule-of-
thumb based on stochastic sampling theory might suggest
that it will be difficult to correct for motions smaller than
half the beamlet grid width. In general, there are many issues
related to the small number of instances that we have used in
these initial examples, and future work will address a num-
ber of these points. One issue of particular interest is the
importance of the tails of the uncertainty distribution: how
important is the incorporation of an instance that represents
the two or three sigma deviations of the distribution?
For the initial examples presented in this work, the as-
sumption was made that the uncertainty distributions are
Gaussian. While this may be reasonable for most situations,
it is easy to think of situations where it is not the appropriate
choice. Breathing causes longer dwell times at the peaks of
inspirations and expiration cycles. A patient laying in a
cradle may have a bimodal state depending on comfort or
other factors clothing, cradle design,¼. The MIGA method
may simulate any kind of distribution—it is certainly not
limited to Gaussians. If these distributions are known, then
they could potentially be approximated within MIGA.
The MIGA approach offers a number of advantages over
other approximations that use motion blurring of the dose
distributions. These blurring techniques do not take into ac-
count changes in geometry shape and do not properly ac-
count for changes in depth and distance from source or
proximity to heterogeneities. While still approximate, the
MIGA approach at least provides accurate calculations for
the individual geometry instances. For deep-seated tumor lo-
cations, this advantage may not always be clinically impor-
tant, but for tumors near the patient’s skin or for sites where
there is significant motion, the accuracy of the calculated
doses could potentially make a crucial difference in the over-
all clinical relevance of the MIGA-based optimized plan.
The accuracy of the MIGA-based planning process can also
be improved if more detailed simulations more instances of
the expected clinical situation are used.
The clinical relevance of a MIGA-based plan optimiza-
tion is of course dependent on how well the simulated geo-
metrical uncertainty distribution correlates with what actu-
ally happens during the patient’s treatments. For example, if
there is an uncorrected systematic shift of the patient’s setup
location vis a vis the central point of the MIGA instance
distribution, the MIGA plan will not be a good representation
of the treatment to be delivered. Of course, this is true for
any prospective estimate of the geometrical setup accuracy
for a specific patient, and in fact this is the main justification
for the current interest in adaptive radiotherapy57 paradigms
that adjust the treatment geometry repeatedly as more indi-
vidualized data on uncertainties for the particular patient are
obtained using daily measurements at each treatment frac-
tion.
While the MIGA approach provides an improvement over
dose blurring techniques to account for motion by provid-
ing explicit dose calculation for a sampling of setup offsets,
it does generally make the initial assumption that there is no
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errors. However, with daily quantitative assessment of the
actual patient setup, it is possible to use the MIGA method-
ology to first generate a “dose-to-date” estimate of the treat-
ments that have been given to date. One can then incorporate
systematic offsets to skew the instance weights or assume
that the offsets are removed, and use MIGA to reoptimize the
balance of the treatment. It is clear that care is needed in
clearly defining the experiments to which the MIGA method
is applied.
Using the multiple instance approximation MIGA to
simulate the distribution of geometries involved in a patient’s
treatment course highlights a basic limitation to most current
treatment planning and optimization approaches. For most
forward and inverse planning, the goals of the treatment are
specified using the total dose to be delivered over the pa-
tient’s treatment course, either as a total dose e.g., 70 Gy,
or a relative dose distribution e.g., prescribe to the 95%
isodose surface. When considering MIGA, or any other
method of dealing with setup uncertainty, the use of only the
total dose to be delivered is a problem. For example, imagine
that a 2-instance MIGA simulation is performed, and that it
turns out that the way that the MIGA optimization achieves a
uniform dose of 70 Gy to the target volume is to give very
unevenly distributed doses to a given voxel e.g.. 50% higher
doses in one instance, and 50% lower dose in the other. The
total dose in all voxels may be 70 Gy, but when the patient is
in one position, the daily dose to the target is significantly
overdosed, while in the other position, it is underdosed.
Clearly, to believe that the MIGA optimization is going to be
clinically useful in this case, the cost function for the opti-
mization should be modified to either 1 force dose/fraction
constraints as well as the total dose costs, or 2 specifically
include dose/fraction corrections into the optimization
through the use of linear/quadratic model estimates of a
bioeffect.58 Although the MIGA simulation may not be an
explicit representation of the actual fractionation of the pa-
tient i.e., one instance for each fraction, the bioeffect mod-
eling still needs to include the fractionation effects in an
explicit way. This is a new level of planning complexity that
has been investigated very little.18,59 Clearly this is a consid-
eration when the dose to a particular region will see different
levels of dose and different dose rates from day to day.
While applying the bioeffect modeling converting dose to
BED biologically effective dose is conceptually easy, the
incorporation of this technique may dramatically increase the
resource requirements and slow the fractionation-corrected
optimization process.
V. CONCLUSIONS
A novel optimization technique that incorporates the
simulation of setup uncertainty and/or patient intratreatment
motion has been developed using a multiple instance of ge-
ometry approximation MIGA method. The MIGA-based
optimization approach simulates the expected distribution of
patient geometries location, anatomy, positioning, and then
optimizes a single IMRT plan using a weighted sum of the
1520 McShan et al.: Optimization with MIGA 1520behavior over all the simulated geometry instances. While in
this first description of the MIGA technique the various in-
stances are all constructed from the initial planning scan set
by duplicating the CT scan set, and then translating each new
dataset to approximate a Gaussian distribution of random
setup errors, the implementation can easily support the use of
distinct measured CT scan sets for example, different parts
of the respiratory cycle, as well as other methods of creating
geometry instances that demonstrate the distortions that oc-
cur due to organ motions, tumor growth, weight loss, etc.
A number of simple examples have demonstrated that it is
possible to use a limited number of instances typically at
least three in each direction while still achieving a good
representation of a Gaussian setup uncertainty distribution.
This same kind of representation total of seven instances, in
three dimensions, has been used to demonstrate significant
improvements in a head and neck IMRT plan over what
would typically occur if PTV expansions of the various
CTVs were used to compensate for the setup uncertainty.
While there are a large number of issues to be investigated
further, both to optimize the use of the method, as well as
determining the best way to make use of the method for
specific clinical protocols or situations, the initial results with
the method are quite promising. A number of clinical and
methodological studies are underway to further investigate
use of the MIGA optimization method described in this
work.
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